Martin Shkreli, the businessman often dubbed the “Pharma Bro,” is back and says he is ready to fight. Multiple Australian outlets report that more than a decade has passed since Shkreli became widely known for sharply increasing the price of a life-saving medication—by about 5,000 per cent—prompting public backlash and intense scrutiny. The articles frame his return as a continuation of his confrontational public profile, with Shkreli positioning himself as combative toward critics and others. While the coverage references his earlier rise to notoriety and the controversy surrounding drug pricing, it does not, in the provided excerpts, detail new legal actions, specific organisations involved, or concrete upcoming events. Instead, the focus is on the fact that Shkreli is again publicly active, emphasizing that his comeback comes after years since the original allegations and widespread criticism that made him one of the most prominent figures associated with pharmaceutical pricing disputes. Overall, the sources present the return as newsworthy largely due to his long-standing reputation stemming from the earlier price increase controversy.